Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PioSpiMet versus ethinylestradiol + levonorgestrel in adolescents with ovarian hyperandrogenism and hyperinsulinemia
2015-005092-24Phase 3Completed
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pioglitazone, spironolactone, metformin, ethinyl estradiol and avatrombopag in Hyperandrogenism and hyperinsulinemia (2 arms), sponsored by Fundació Sant Joan de Déu. Primary endpoints: Ovulatory frequency, Insulin sensitivity and 4 more. Started Jan 2016; status: completed.
02
Drugs
pioglitazonespironolactonemetforminethinyl estradiolavatrombopag
03
Conditions
Hyperandrogenismhyperinsulinemia
Beyond the preview
Go deeper on 2015-005092-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005092-24.